Quebec News Tribune – Lifestyle
Author:
Aprea Therapeutics
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
May 13, 2026
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
April 21, 2026
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
April 1, 2026
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
March 30, 2026
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
March 30, 2026
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
March 16, 2026